Don’t forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!
Andrea Ciorba, Virginia Corazzi, Piotr H. Skarżyński, Magdalena B. Skarżyńska, Chiara Bianchini, Stefano Pelucchi, Stavros Hatzopoulos
Abstract
Aim of this communication is to remind clinical professionals to be aware of ototoxic side effects of several specific drugs proposed for the treatment of the new virus SARS-CoV-2 (Covid-19). In particular, chloroquine and hydroxychloroquine, azithromycin, as well as antiviral drugs such as remdesivir, favipiravir and lopinavir can all present potential ototoxic side effects. The data in the literature do not offer specific information on their potential synergetic effects nor on their interactions.
Topics & Concepts
HydroxychloroquineFavipiravirAzithromycinCoronavirus disease 2019 (COVID-19)MedicineLopinavirOtotoxicityChloroquinePandemicSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakIntensive care medicineVirologyImmunologyOutbreakBiologyInternal medicineAntibioticsDiseaseMalariaCisplatinMicrobiologyInfectious disease (medical specialty)ChemotherapyVestibular and auditory disordersHearing, Cochlea, Tinnitus, GeneticsOlfactory and Sensory Function Studies